Healio.com/Hepatology has compiled a list of the latest, most
relevant research on hepatitis C virus infection presented recently at
ICAAC 2014 in Washington, D.C.
genotype 1b achieved sustained virologic response at 12 weeks during
treatment with a three direct-acting antiviral regimen with or without
ribavirin. Read more
retrospective survey of data from the National Spanish System for
Hospital Data between 1997 and 2010 was performed to determine the
number of people hospitalized with hepatitis C virus and diabetes.
Researchers said the number of patients hospitalized and coinfected
with HCV and diabetes in Spain increased during a 14-year period.
therapeutic guidelines directed toward the control of glycemia and the
reduction of insulin resistance in HCV-positive patients may help to
reduce the hospital burden of the disease,” the researchers wrote. Read more
genotype 1 included in the SAPPHIRE-I and II phase 3 clinical trials
experienced a low rate of study drug-related serious adverse events and
study drug discontinuations during treatment with direct-acting
antivirals and ribavirin.
Researchers randomly assigned 1,025 patients to a three direct-acting
antiviral regimen of ABT-450/ritonavir, ombitasvir and dasabuvir plus
ribavirin or matching placebos for 12 weeks.
“AbbVie’s three DAA plus RBV regimen was generally well-tolerated by the selected patient population,” Tolga Baykal, MD, of AbbVie, told Healio.com/Hepatology. Read more